Skip to main content

Advertisement

SpringerLink
Log in

Selenoprotein P levels in patients with diabetes mellitus with complications

  • Original Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

Abstract

Aims

Increasing evidence has shown that selenoprotein P levels are elevated in type 2 diabetes mellitus and are associated with insulin resistance and release. This study aimed to determine if there was a connection between selenoprotein P levels and metabolic parameters in patients with diabetes with microvascular complications.

Methods

Serum selenoprotein P concentrations were measured by ELISA in 44 patients with diabetes with complications and 36 patients with diabetes without complications.

Results

There was no statistically significant difference in selenoprotein P levels between the groups [1.9 (0.9–2.6) and 1.9 (0.8–2.4) ng/mL, respectively, p = 0.565]. Selenoprotein P, glucose, glycosylated hemoglobin, C-reactive protein, triglycerides, total cholesterol, and low-density lipoprotein cholesterol levels were not statistically significantly correlated in patients with complications. However, there was a significant correlation with high-density lipoprotein cholesterol (r = − 0.401, p = 0.042).

Conclusions

We did not find high selenoprotein P levels in patients with complications, but its inverse association with high-density lipoprotein cholesterol indicates that it may play a role in developing cardiovascular disease in this community of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

The data that support the findings of this study are available on request from the corresponding author.

References

  1. Atlas IDFID. 9th edn.(2019), 2020.

  2. Litwak L, Goh S-Y, Hussein Z, Malek R, Prusty V, Khamseh ME. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational a 1 chieve study. Diabetology & metabolic syndrome. 2013;5:1–10.

    Article  Google Scholar 

  3. Association AD. 6. Glycemic targets: standards of medical care in diabetes—2021. Diabetes Care. 2021;44:S73–84.

    Article  Google Scholar 

  4. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of diabetes (EASD). Eur Heart J. 2019;41:255–323.

    Article  Google Scholar 

  5. Stefan N, Haring HU. The role of hepatokines in metabolism. Nat Rev Endocrinol. 2013;9:144–52.

    Article  CAS  Google Scholar 

  6. Brodin O, Hackler J, Misra S, Wendt S, Sun Q, Laaf E, et al. Selenoprotein P as biomarker of selenium status in clinical trials with therapeutic dosages of selenite. Nutrients. 2020;12:1067.

    Article  CAS  Google Scholar 

  7. Hill KE, Wu S, Motley AK, Stevenson TD, Winfrey VP, Capecchi MR, et al. Production of selenoprotein P (Sepp1) by hepatocytes is central to selenium homeostasis. J Biol Chem. 2012;287:40414–24.

    Article  CAS  Google Scholar 

  8. Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, Kurita S, et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 2010;12:483–95.

    Article  CAS  Google Scholar 

  9. Mita Y, Nakayama K, Inari S, Nishito Y, Yoshioka Y, Sakai N, et al. Selenoprotein P-neutralizing antibodies improve insulin secretion and glucose sensitivity in type 2 diabetes mouse models. Nat Commun. 2017;8:1–17.

    Article  CAS  Google Scholar 

  10. Oo SM, Misu H, Saito Y, Tanaka M, Kato S, Kita Y, et al. Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population. Sci Rep. 2018;8:1–10.

    Article  CAS  Google Scholar 

  11. Yang SJ, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab. 2011;96:E1325–9.

    Article  CAS  Google Scholar 

  12. Ali SA, Nassif WM, Abdelaziz DH. Alterations in serum levels of fetuin a and selenoprotein P in chronic hepatitis C patients with concomitant type 2 diabetes: a case-control study. Clinics and research in hepatology and gastroenterology. 2016;40:465–70.

    Article  CAS  Google Scholar 

  13. Zhang Q, Li W, Wang J, Hu B, Yun H, Guo R, et al. Selenium levels in community dwellers with type 2 diabetes mellitus. Biol Trace Elem Res. 2019;191:354–62.

    Article  CAS  Google Scholar 

  14. Altinova AE, Iyidir OT, Ozkan C, Ors D, Ozturk M, Gulbahar O, et al. Selenoprotein P is not elevated in gestational diabetes mellitus. Gynecol Endocrinol. 2015;31:874–6.

    Article  CAS  Google Scholar 

  15. Roman M, Lapolla A, Jitaru P, Sechi A, Cosma C, Cozzi G, et al. Plasma selenoproteins concentrations in type 2 diabetes mellitus—a pilot study. Transl Res. 2010;156:242–50.

    Article  CAS  Google Scholar 

  16. Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study). Diabetes Care. 2019;42:416–26.

    Article  CAS  Google Scholar 

  17. Femlak M, Gluba-Brzózka A, Ciałkowska-Rysz A, Rysz J. The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. Lipids Health Dis. 2017;16:1–9.

    Article  Google Scholar 

  18. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58:886–99.

    Article  Google Scholar 

  19. Schomburg L, Orho-Melander M, Struck J, Bergmann A, Melander O. Selenoprotein-p deficiency predicts cardiovascular disease and death. Nutrients. 2019;11:1852.

    Article  CAS  Google Scholar 

  20. Speckmann B, Sies H, Steinbrenner H. Attenuation of hepatic expression and secretion of selenoprotein P by metformin. Biochem Biophys Res Commun. 2009;387:158–63.

    Article  CAS  Google Scholar 

  21. Saito Y, Misu H, Takayama H, Takashima SI, Usui S, Takamura M, et al. Comparison of human selenoprotein P determinants in serum between our original methods and commercially available kits. Biol Pharm Bull. 2018;41:828–32.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the Scientific Research Projects Unit of Kırşehir Ahi Evran University.

Funding

This study was supported by Kırsehir Ahi Evran University Scientific Research Projects Unit.

Author information

Authors and Affiliations

  1. Faculty of Medicine, Department of Medical Biochemistry, Kirsehir Ahi Evran University, Kervansaray, 2019. Sk. No:1, 40200, Kirsehir, Turkey

    Bilal Ilanbey

  2. Faculty of Medicine, Department of Internal Medicine, Kirsehir Ahi Evran University, Kirsehir, Turkey

    Hasan Esat Yücel & Cahit Uçar

  3. Faculty of Medicine, Department of Ophthalmology, Kirsehir Ahi Evran University, Kirsehir, Turkey

    Özkan Kocamış

Authors
  1. Bilal Ilanbey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hasan Esat Yücel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cahit Uçar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Özkan Kocamış
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bilal Ilanbey.

Ethics declarations

Ethics approval

Kırsehir Ahi Evran University Faculty of Medicine approved the study of Medicine Ethics Committee (approval date and number: 2020-04/31). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

All of the authors confirm the publication.

Conflict of interest/competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ilanbey, B., Yücel, H.E., Uçar, C. et al. Selenoprotein P levels in patients with diabetes mellitus with complications. Int J Diabetes Dev Ctries 42, 735–740 (2022). https://doi.org/10.1007/s13410-021-01029-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-021-01029-0

Keywords

Search

Navigation